By Eric Brand

Here is an interesting article from Taiwan on Du Huo Ji Sheng Tang. The article assesses several products on the market for the presence of aristolochic acid (AA), which would come from the presence of Xi Xin in Du Huo Ji Sheng Tang. Essentially the conclusion of the article was that Du Huo Ji Sheng Tang basically lacked significant levels of AA and was not associated with nephotoxicity in the patient population that was studied.

...

The authors note that their preliminary analysis of National Health Insurance data found that about 1.57 million patient prescriptions in Taiwan have included Xi Xin. Du Huo Ji Sheng Tang was prescribed to 725,549 patients between 1996 and 2004.

Here's the full text:
http://www.cmjournal.org/content/5/1/6